Activity from announced rounds
Cooley, also named Cooley LLP, is a law firm that Steward and Superluminal identify as an investor in their announcements.
Steward automates AML and KYC work for investor onboarding. Superluminal develops small-molecule medicines using structural biology, protein dynamics, machine learning and experiments. These disclosed investment relationships are distinct from Cooley’s separate role as legal counsel in other transactions.
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.